Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …

Chronic HBV infection is a global public health burden estimated to impact nearly 300
million persons worldwide. Despite the advent of potent antiviral agents that effectively …

Background & Aims Functional cure, defined based on hepatitis B surface antigen (HBsAg)
loss, is rare during nucleos (t) ide analogue (NA) therapy and guidelines on finite NA …

Background Xalnesiran, a small interfering RNA molecule that targets a conserved region of
the hepatitis B virus (HBV) genome and silences multiple HBV transcripts, may have …

Hepatitis B virus (HBV) chronically infects 296 million people worldwide and causes more
than 820,000 deaths annually due to cirrhosis and hepatocellular carcinoma. Current …

Background & Aims RNA interference therapy has been shown to reduce hepatitis B surface
antigen (HBsAg) levels in preclinical models, which could confer functional cure in patients …

Background and Aims Data regarding outcome of COVID‐19 in patients with autoimmune
hepatitis (AIH) are lacking. Approach and Results We performed a retrospective study on …

Despite the availability of effective vaccines and antiviral therapy over the past two to three
decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a …

Background & Aims The persistence of covalently closed circular DNA (cccDNA) in infected
hepatocytes is the major barrier preventing viral eradication with existing therapies in …

Hepatocellular carcinoma reduced, HBsAg loss increased, and... : Hepatology Hepatocellular
carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis …